SCD1 inhibitor-3 |
| Catalog No.GC68445 |
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1282606-48-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1].
SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1].
SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1].
| Animal Model: | Lewis rats[1] |
| Dosage: | 5 mg/kg |
| Administration: | P.o.; 4 hours |
| Result: | Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. |
| Animal Model: | Lewis rats[1] |
| Dosage: | 2~10 mg/kg |
| Administration: | P.o.; 4 hours |
| Result: | A dose-responsive reduction of plasma triglycerides desaturation index. |
[1]. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *